NRx Pharmaceuticals starts ketamine sales effort ahead of January shipments

Hospital sales outreach has begun ahead of January deliveries as NRx Pharmaceuticals, Inc. NASDAQNRXP said on Wednesday it activated a 17-person team for U.S.-made preservative-free ketamine. NRx expects gross and net sales margins above 50 per cent, although the launch release discloses no product price or purchase quantities.

The Nov. 11 announcement targets initial supply agreements and preorders in late 2026, followed by shipments in January 2027. The start of sales operations therefore precedes scheduled product deliveries.

NRx is a small U.S. biopharmaceutical company developing central nervous system treatments and commercializing sterile injectable medicines.

Shares closed at US$2.36 on Nasdaq at 4 p.m. EST on Nov. 10, down 0.84 per cent, according to the NASDAQNRXP quote page. That close predates Wednesday's announcement and does not measure its trading response.

The Oct. 30 approval announcement concerned an Abbreviated New Drug Application, the generic-drug route. NRx separately says it is seeking approval for intravenous ketamine, called NRX-100, with depression and suicidality claims; Wednesday's launch supplies no new psychiatric indication.

Packaging And Sales Costs Drive Margin Forecasts

Privately held Nephron Pharmaceuticals confirmed on Nov. 2 that the product will be manufactured at its West Columbia, South Carolina, campus. NRx is organizing the commercial effort and announced the generic approval in October.

The Nov. 11 release describes blow-fill-seal manufacturing, which forms, fills and seals a polypropylene container in a single step. A luer-lock tip connects directly to a sterile syringe, eliminating the separate needle used to withdraw medicine from conventional glass containers.

NRx estimates manufacturing costs below 20 per cent of the sales price, against 70 per cent or more in its experience with glass-bottled drugs. Those figures and the margin outlook are company estimates, rather than reported commercial results for the new product.

"By enlisting seasoned sales representatives who already sell sterile injectable drugs, we are able to drive considerable efficiency in costs of sales and marketing," NRx chief executive Jonathan Javitt said in the release.

The company says its representatives have relationships with purchasers responsible for approximately 80 per cent of current U.S. ketamine sales. That is its estimate of customer reach, rather than secured market share.

NRx reports an initial two-year expiration for the product and says it anticipates extending that period. The announcement gives no date or revised shelf life for that extension.

NRx also says it has contracted for additional German-made equipment to double its South Carolina manufacturing footprint. The release gives no installation date or output capacity for that expansion.

Generic Supply And Depression Development Remain Separate

Existing suppliers include Pfizer Inc. NYSEPFE, whose ketamine prescribing information, revised in May 2026, lists diagnostic and surgical anaesthesia uses. That label warns of respiratory depression and elevated blood pressure; Wednesday's NRx release supplies no comparative patient-safety trial.

For supply context, NRx said on Nov. 11 that ketamine has been in shortage since 2018 and that customers have expressed willingness to enter longer-term agreements for guaranteed supply. The announcement does not quantify how much additional demand its planned shipments would cover.

In the separate depression-development market, Compass Pathways plc NASDAQCMPS announced on Nov. 9 completion of its COMP360 psilocybin application for treatment-resistant depression. Its expected first-half 2027 launch remains subject to FDA approval.

Read more: Compass Pathways reports completion of COMP360 psilocybin application

NRx targets initial supply agreements and preorders in late 2026. Shipments are scheduled to begin in January 2027, the first delivery milestone for its new sales operation.